Article Text

Download PDFPDF
The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer
  1. Mette Hjortkjær1,2,3,
  2. Mads Malik Aagaard Jørgensen4,
  3. Marianne Waldstrøm2,5,
  4. Dorthe Ørnskov5,
  5. Erik Søgaard-Andersen3,
  6. Anders Jakobsen1,2 and
  7. Karina Dahl-Steffensen1,2
  1. 1 Department of Oncology, Vejle Hospital, Vejle, Denmark
  2. 2 Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
  3. 3 Department of Gynecology and Obstetrics, Aalborg University Hospital, Aalborg, Denmark
  4. 4 Clinical Genetics, Vejle Hospital, Vejle, Denmark
  5. 5 Department of Pathology, Vejle Hospital, Vejle, Denmark
  1. Correspondence to Mette Hjortkjær, Department of Oncology, Vejle Hospital, DK-7100 Vejle, Denmark;methjo{at}rm.dk

Abstract

Objective Germline mutations in BRCA1/2 genes predict improved survival and sensitivity to treatment with poly(adenosine-diphosphate-ribose) polymerase inhibitors in epithelial ovarian carcinoma. The prognostic importance of other genetic alterations leading to homologous recombination deficiency, collectively BRCAness phenotype, is unresolved. The aim was to analyze the distribution of homologous recombination deficiency in epithelial ovarian carcinoma caused by mutations in a panel of homologous recombination genes (including BRCA1/2) or epigenetic alterations. A further aim was to investigate the prognostic importance of homologous recombination deficiency, the BRCAness phenotype.

Methods We assessed 380 patient specimens from a Danish population-based epithelial ovarian carcinoma cohort for germline and somatic mutations in 18 different homologous recombination genes, including BRCA1 and BRCA2, using next generation sequencing. Epigenetic alteration due to BRCA1 hypermethylation was assessed by pyrosequencing and BRCA1 protein expression was evaluated by immunohistochemistry.

Results Seventeen percent of patients with epithelial ovarian carcinoma carried a germline (9.8%) and/or somatic (6.3%) mutation in 12 (BRCA1, BRCA2, CHEK2, ATM, RAD51D, EMSY, PALB2, BRIP1, ERCC1, RAD50, ATR, RAD51C) of 18 sequenced homologous recombination genes. The homologous recombination mutation rate was similar among the different histologic subtypes, however the type of mutation (BRCA1/2 and other homologous recombination mutations) differed, p=4×10-4. BRCA1 hypermethylation was present in 7.4% of patient specimens for a total BRCAness phenotype of 23.9%. The BRCAness phenotype was associated with improved overall survival in the high-grade serous carcinoma subgroup with a median overall survival of 4.4 years (95% CI 3.0 to 5.3) versus 2.2 years (95% CI 1.9 to 2.4) in BRCAness wildtype, p=0.0002. Multivariate analysis confirmed an independent prognostic value of the BRCAness phenotype among the high-grade serous carcinoma subgroup, hazard ratio 0.65 (95% CI 0.47 to 0.92), p=0.014.

Conclusions The BRCAness phenotype is present in almost one-fourth of epithelial ovarian carcinoma and holds important prognostic information. The implications of our findings in relation to poly(adenosine-diphosphate-ribose) polymerase inhibitor treatment call for further investigation.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding The study was in part funded by the Research Council of Vejle Hospital.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.